2023-2024年度美国商业保险人群中6月龄至64岁个体接种流感疫苗后健康结局的安全性监测:自身对照病例系列分析
本研究采用自身对照病例系列分析,利用3个商业数据库评估2023-2024年度流感疫苗在6月龄至64岁商业保险人群中的安全性。结果显示,除热性惊厥和短暂性脑缺血发作外,其余结局风险均无统计学显著升高。标准剂量或任何流感疫苗接种后0-1天热性惊厥风险轻度升高,1-21天短暂性脑缺血发作风险轻度升高。
要点
- 2023-2024年度流感疫苗在6月龄至64岁人群中总体安全性良好,大多数结局风险无统计学显著升高。
- 标准剂量或任何流感疫苗接种后0-1天热性惊厥风险轻度升高,IRR分别为1.68和1.67。
- 标准剂量或任何流感疫苗接种后1-21天短暂性脑缺血发作风险轻度升高,IRR分别为1.28和1.29。
核心结论
- 2023-2024年度流感疫苗接种后不良健康结局风险极小,但需持续监测每年重新配制的季节性疫苗安全性。
- 接种后热性惊厥和短暂性脑缺血发作的潜在风险须与季节性流感疫苗接种的已知获益仔细权衡。
研究设计与样本
- 采用自身对照病例系列分析,比较接种后预设风险间期与对照间期的九种安全性结局发生率。
- 数据来源为3个商业数据库,纳入6月龄至64岁商业保险个体,观察2023-2024年度任何季节性流感疫苗接种。
- 使用条件泊松回归估计发病率比(IRR)及95%置信区间(CI),并按结局特异性季节性模式调整。
主要发现
- 合并Meta分析显示,除热性惊厥和短暂性脑缺血发作外,任何结局风险均无统计学显著升高。
- 标准剂量疫苗接种后0-1天热性惊厥风险轻度但统计学显著升高(IRR:1.68;95% CI:1.17,2.43),任何流感疫苗接种后亦升高(IRR:1.67;95% CI:1.16,2.41)。
- 标准剂量疫苗接种后1-21天短暂性脑缺血发作风险统计学显著升高(IRR:1.28;95% CI:1.04,1.59),任何流感疫苗接种后亦升高(IRR:1.29;95% CI:1.05,1.59)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza vaccines are reformulated annually to target expected virus strains for the upcoming season. Although the safety of seasonal influenza vaccines is well-established, active safety surveillance of reformulated vaccines is essential to assess occurrence of potential health outcomes among vaccinated individuals. This study evaluated the safety of the 2023-2024 influenza vaccines among U.S. commercially insured individuals aged 6 months to 64 years. METHODS: We used a self-controlled case series analysis to compare incidence rates of nine safety outcomes following any 2023-2024 seasonal influenza vaccination in pre-specified post-vaccination risk and control intervals among commercially-insured individuals 6 months to 64 years from 3 commercial databases. Outcomes of interest were anaphylaxis, encephalitis/encephalomyelitis/acute disseminated encephalomyelitis, Guillain-Barré syndrome, febrile seizure, transverse myelitis, hemorrhagic stroke, non-hemorrhagic stroke (NHS), transient ischemic attack (TIA), and NHS or TIA. We used conditional Poisson regression to estimate incidence rate ratios (IRRs) and 95 % confidence intervals (CIs), adjusted for outcome-specific seasonality patterns. RESULTS: We observed nearly 10 million influenza vaccinees across the databases. Combined meta-analysis showed no statistically significant elevation in risk for any outcome except febrile seizure and TIA. A small, statistically significant elevation in risk was observed for febrile seizure (0-1-day risk interval) following standard-dose (IRR: 1.68; [95 % CI: 1.17, 2.43]) or any (IRR: 1.67; [1.16, 2.41]) influenza vaccine. We also observed a statistically significant elevation in risk for TIA (1-21-day risk interval) following a standard-dose (IRR: 1.28; [1.04, 1.59]) or any (IRR: 1.29; [1.05, 1.59]) influenza vaccine. CONCLUSION: Results from this study show that the risk of adverse health outcomes following the 2023-2024 influenza vaccination was minimal. Continued surveillance is necessary to monitor the safety of annually reformulated seasonal vaccines. The potential risk of febrile seizures and TIA following vaccination must be carefully considered with the known benefits of seasonal influenza vaccination.
引用
- Lloyd PC, Acharya G, Zhao H, et al. Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses. Vaccine. 2025. PMID: 40845790. doi:10.1016/j.vaccine.2025.127614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。